ArticleAntimicrobial agents and chemotherapy2010
The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Targeting biofilm and virulence inMicrobiology spectrum · 2026Article
- Antimicrobial Resistance Trends, Resistance Mechanisms, and Antibiotic Consumption in COVID-19 Versus Non-COVID-19 Units: A Seven-Year Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2025Article
- Proteomic and metabolomic responses of priority bacterial pathogens to subinhibitory concentration of antibiotics.npj antimicrobials and resistance · 2025Article
- Proteomic Insights into Bacterial Responses to Antibiotics: A Narrative Review.International journal of molecular sciences · 2025Review
- A role for the stringent response in ciprofloxacin resistance in Pseudomonas aeruginosa.Scientific reports · 2024Article
- Adaptive response ofMicrobiology (Reading, England) · 2024Article
- Deferiprone-Gallium-Protoporphyrin Chitogel DecreasesMaterials (Basel, Switzerland) · 2024Article
- Anti-quorum sensing potential of selenium nanoparticles against LasI/R, RhlI/R, and PQS/MvfR inFrontiers in molecular biosciences · 2023Article
- Comparison of freeze-thaw and sonication cycle-based methods for extracting AMR-associated metabolites fromFrontiers in microbiology · 2023Article
- Article
- Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment.PLoS pathogens · 2020Article
- The Role of Proteomics in Bacterial Response to Antibiotics.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Effect of Biosynthesized ZnO Nanoparticles on Multi-Drug Resistant Pseudomonas Aeruginosa.Antibiotics (Basel, Switzerland) · 2020Article
- Article
- A Pilot Study of the Synergy between Two Antimicrobial Peptides and Two Common Antibiotics.Antibiotics (Basel, Switzerland) · 2019Article
- Antiquorum sensing activity of silver nanoparticles inIn silico pharmacology · 2017Article
- Siderophores in Iron Metabolism: From Mechanism to Therapy Potential.Trends in molecular medicine · 2016Review
- Article
- Lactonase-expressing Lactobacillus plantarum NC8 attenuates the virulence factors of multiple drug resistant Pseudomonas aeruginosa in co-culturing environment.World journal of microbiology & biotechnology · 2014Article
- Comparative genome analysis of ciprofloxacin-resistant Pseudomonas aeruginosa reveals genes within newly identified high variability regions associated with drug resistance development.Microbial drug resistance (Larchmont, N.Y.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Microbes have developed resistance to nearly every antibiotic, yet the steps leading to drug resistance remain unclear. Here we report a multistage process by which Pseudomonas aeruginosa acquires drug resistance following exposure to ciprofloxacin at levels ranging from 0.5× to 8× the initial MIC. In stage I, susceptible cells are killed en masse by the exposure. In stage II, a small, slow to nongrowing population survives antibiotic exposure that does not exhibit significantly increased resistance according to the MIC measure. In stage III, exhibited at 0.5× to 4× the MIC, a growing population emerges to reconstitute the population, and these cells display heritable increases in drug resistance of up to 50 times the original level. We studied the stage III cells by proteomic methods to uncover differences in the regulatory pathways that are involved in this phenotype, revealing upregulation of phosphorylation on two proteins, succinate-semialdehyde dehydrogenase (SSADH) and methylmalonate-semialdehyde dehydrogenase (MMSADH), and also revealing upregulation of a highly conserved protein of unknown function. Transposon disruption in the encoding genes for each of these targets substantially dampened the ability of cells to develop the stage III phenotype. Considering these results in combination with computational models of resistance and genomic sequencing results, we postulate that stage III heritable resistance develops from a combination of both genomic mutations and modulation of one or more preexisting cellular pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.